Exact Mass: 421.1862288
Exact Mass Matches: 421.1862288
Found 120 metabolites which its exact mass value is equals to given mass value 421.1862288
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Latrunculin A
C22H31NO5S (421.19228360000005)
A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.
4-Hydroxytoremifene
C26H28ClNO2 (421.18084580000004)
latrunculin a
C22H31NO5S (421.19228360000005)
Linsitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Linsitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
N-[4-[3-(4-Oxo-5,5-dimethyl-4,5-dihydrofuran-2-yl)butoxy]phenethyl]-3-(methylsulfinyl)propanamide
C22H31NO5S (421.19228360000005)
(E)-3-(methylsulfonyl)-propenoic acid (2E,6E)-4-(8-hydroxy-3,7-dimethyl-2,6-octadienyloxy)-phenethyl amide|gerambullol
C22H31NO5S (421.19228360000005)
apo latrunculin T
C22H31NO5S (421.19228360000005)
A natural product found in Cacospongia mycofijiensis.
Ala Ala Phe Asn
Ala Ala Asn Phe
Ala Phe Ala Asn
Ala Phe Gly Gln
Ala Phe Asn Ala
Ala Phe Gln Gly
Ala Gly Phe Gln
Ala Gly Gln Phe
Ala Asn Ala Phe
Ala Asn Phe Ala
Ala Gln Phe Gly
Ala Gln Gly Phe
Phe Ala Ala Asn
Phe Ala Gly Gln
Phe Ala Asn Ala
Phe Ala Gln Gly
Phe Gly Ala Gln
Phe Gly Gln Ala
Phe Asn Ala Ala
Phe Gln Ala Gly
Phe Gln Gly Ala
Gly Ala Phe Gln
Gly Ala Gln Phe
Gly Phe Ala Gln
Gly Phe Gln Ala
Gly Gln Ala Phe
Gly Gln Phe Ala
Asn Ala Ala Phe
Asn Ala Phe Ala
Asn Phe Ala Ala
Asn Ser Thr Thr
C15H27N5O9 (421.18086919999996)
Asn Thr Ser Thr
C15H27N5O9 (421.18086919999996)
Asn Thr Thr Ser
C15H27N5O9 (421.18086919999996)
Gln Ala Phe Gly
Gln Ala Gly Phe
Gln Phe Ala Gly
Gln Phe Gly Ala
Gln Gly Ala Phe
Gln Gly Phe Ala
Gln Ser Ser Thr
C15H27N5O9 (421.18086919999996)
Gln Ser Thr Ser
C15H27N5O9 (421.18086919999996)
Gln Thr Ser Ser
C15H27N5O9 (421.18086919999996)
Ser Asn Thr Thr
C15H27N5O9 (421.18086919999996)
Ser Gln Ser Thr
C15H27N5O9 (421.18086919999996)
Ser Gln Thr Ser
C15H27N5O9 (421.18086919999996)
Ser Ser Gln Thr
C15H27N5O9 (421.18086919999996)
Ser Ser Thr Gln
C15H27N5O9 (421.18086919999996)
Ser Thr Asn Thr
C15H27N5O9 (421.18086919999996)
Ser Thr Gln Ser
C15H27N5O9 (421.18086919999996)
Ser Thr Ser Gln
C15H27N5O9 (421.18086919999996)
Ser Thr Thr Asn
C15H27N5O9 (421.18086919999996)
Thr Asn Ser Thr
C15H27N5O9 (421.18086919999996)
Thr Asn Thr Ser
C15H27N5O9 (421.18086919999996)
Thr Gln Ser Ser
C15H27N5O9 (421.18086919999996)
Thr Ser Asn Thr
C15H27N5O9 (421.18086919999996)
Thr Ser Gln Ser
C15H27N5O9 (421.18086919999996)
Thr Ser Ser Gln
C15H27N5O9 (421.18086919999996)
Thr Ser Thr Asn
C15H27N5O9 (421.18086919999996)
Thr Thr Asn Ser
C15H27N5O9 (421.18086919999996)
Thr Thr Ser Asn
C15H27N5O9 (421.18086919999996)
FIPI
C23H24FN5O2 (421.19139359999997)
FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research[1][2][3].
1-Methyl-2-(tributylstannyl)-1H-indole
C21H35NSn (421.17913400000003)
4-(Naphthalenyl)-N-[4-(1-naphthalenyl)phenyl]benzenamine
(2-{4-[(E)-2-Chloro-1,2-diphenylvinyl]phenoxy}ethyl)diethylamine oxide
C26H28ClNO2 (421.18084580000004)
N~3~-[5-(1h-Indol-6-Yl)-2-(Pyridin-2-Ylmethoxy)benzyl]pyridine-2,3-Diamine
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(1-hydroxy-3-methylhexan-3-yl)sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
C17H31N3O7S (421.18826160000003)
4-[(4Z,8E,10Z)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-1,3-thiazolidin-2-one
C22H31NO5S (421.19228360000005)
5-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-1H-indole-2-carboxamide
C23H24FN5O2 (421.19139359999997)
FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research[1][2][3].
{2-[N-(4-Dimethylamino-benzylidene)-hydrazino]-6-methyl-5-nitro-pyrimidin-4-yl}-(4-methoxy-phenyl)-amine
Ascofuranol(1-)
C23H30ClO5- (421.17816600000003)
A phenolate anion resulting from the deprotonation of the hydroxy group that is para- to the aldehyde group of ascofuranol. The major species at pH 7.3.
(3S,6aR,8R,10aR)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(methylamino)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C20H27N3O7 (421.18489120000004)
1-[(2R,3R,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2,5-difluorophenyl)urea
1-[(2R,3S,6S)-6-[2-(4-cyclopropyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2,5-difluorophenyl)urea
1-[(2R,3R,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2,5-difluorophenyl)urea
1-[(2S,3R,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2,5-difluorophenyl)urea
1-[(2S,3S,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2,5-difluorophenyl)urea
1-[(2S,3R,6R)-6-[2-(4-cyclopropyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2,5-difluorophenyl)urea
1-[(2S,3S,6S)-6-[2-(4-cyclopropyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2,5-difluorophenyl)urea
1-[(2R,3S,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2,5-difluorophenyl)urea
1-Chloro-4-[4-[2-(dimethylamino)ethoxy]phenyl]-3,4-diphenylbut-3-en-2-ol
C26H28ClNO2 (421.18084580000004)
(2-{4-[3-(2-Chloroethyl)-2,3-diphenyloxiran-2-yl]phenoxy}ethyl)dimethylamine
C26H28ClNO2 (421.18084580000004)
(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-5-(4-hydroxybenzoyl)oxy-6-methyloxan-2-yl]oxynon-2-enoate
TAK-071
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM[1].
(2e)-n-[2-(4-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-3-hydroxyphenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid
C22H31NO5S (421.19228360000005)
(1r,4z,8e,10z,12s,15r,17r)-17-hydroxy-17-[(4s)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-3-one
C22H31NO5S (421.19228360000005)
n-(2-{4-[(3s)-3-(5,5-dimethyl-4-oxofuran-2-yl)butoxy]phenyl}ethyl)-3-[(r)-methanesulfinyl]propanimidic acid
C22H31NO5S (421.19228360000005)
20-butoxy-17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaene
C25H27NO5 (421.18891320000006)
17-hydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-3-one
C22H31NO5S (421.19228360000005)